Columbia Laboratories (CBRX) Finishes Treatment Phase of PROCHIEVE Phase III Study
More News related to CBRX
- "CRINONE(R) 8% (progesterone vaginal gel) As Effective as Hormone Injections During IVF" Is Medscape's "Top News" from The ASRM 65th Annual Meeting
- Columbia Laboratories Reports Third Quarter 2009 Financial Results
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- Columbia Laboratories Closes Registered Direct Common Stock and Warrant Offering
- Columbia Laboratories to Present at the Oppenheimer 20th Annual Healthcare Conference on November 3, 2009
More News related to FDA
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
Columbia Laboratories, Inc. (NASDAQ: CBRX) announced it has completed the treatment phase of its pivotal Phase III clinical study of PROCHIEVE 8% (progesterone gel) to prevent recurrent preterm birth. This 669-patient randomized, double-blind, placebo-controlled clinical trial is the largest preterm prevention study ever conducted. The ultimate goal of this program is to expand the PROCHIEVE 8% label beyond infertility and secondary amenorrhea, for which it is currently FDA-approved and commercially available, to include the prevention of recurrent preterm birth.
Related Categories
FDAStocks Mentioned
+0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
